Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty liver disease.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 or 3 fibrosis.